Evidence map›Paper›PMID 37395930›Full record

ReviewAmerican journal of clinical dermatology2023

Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies.

Christopher J Fay, Samantha Jakuboski, Beth Mclellan, Blair S Allais, Yevgeniy Semenov, Cecilia A Larocca, Nicole R LeBoeuf

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of clinical dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Christopher J FayDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3278-1417
Samantha JakuboskiLoyola University Stritch School of Medicine, Maywood, IL, USA.
Beth MclellanDepartment of Dermatology, Albert Einstein College of Medicine, Bronx, NY, USA.
Blair S AllaisDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Yevgeniy SemenovDepartment of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Cecilia A LaroccaDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA.
Nicole R LeBoeufDepartment of Dermatology, Brigham and Women's Hospital, and the Center for Cutaneous Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. nleboeuf@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-8264-834X
Brigham and Women's Hospital · USAlbert Einstein College of Medicine · USHarvard University · USLoyola University Chicago · US

Funding

Predictive modeling of cutaneous immune checkpoint inhibitor toxicitiesK23AR080791 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Yevgeniy R Semenov · 2023 to 2026
$704k
NCI NIH HHS L30 CA264747NIAMS NIH HHS K23 AR080791
6 · The paper itself

Abstract

The advent of protein kinase inhibitors and immunotherapy has profoundly improved the management of advanced melanoma. However, with these therapeutic advancements also come drug-related toxicities that have the potential to affect various organ systems. We review dermatologic adverse events from targeted (including BRAF and MEK inhibitor-related) and less commonly used melanoma treatments, with a focus on diagnosis and management. As immunotherapy-related toxicities have been extensively reviewed, herein, we discuss injectable talimogene laherparepvec and touch on recent breakthroughs in the immunotherapy space. Dermatologic adverse events may severely impact quality of life and are associated with response and survival. It is therefore essential that clinicians are aware of their diverse presentations and management strategies.

Indexed as

MelanomaOncolytic VirotherapySkin NeoplasmsHumansImmunotherapyProtein Kinase InhibitorsProto-Oncogene Proteins B-rafQuality of LifeProtein Kinase InhibitorsProto-Oncogene Proteins B-raf

Identifiers

PMID37395930
PMCPMC10796164
OpenAlexW4382919459

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.